🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Bicara Therapeutics Inc. (BCAX)
NASDAQ: BCAX · Real-Time Price · USD
9.38
-0.22 (-2.29%)
At close: Nov 18, 2026, 4:00 PM EST
9.24
-0.14 (-1.49%)
Pre-market: Nov 19, 2026, 4:01 AM EST
← View all transcripts

Jefferies Global Healthcare Conference

Nov 16, 2026

Summary

Ficera showed deep, durable responses in HPV-negative head and neck cancer, while FORTIFI-HN01 has substantial enrollment and top-line data are expected mid-next year. A 650-patient trial includes a planned interim OS analysis; first CRC data are expected at ASCO GI in January.

Speaker 1

Good afternoon, everyone. We'll be starting. Hope you guys are having a great conference. It is my pleasure to introduce Ryan Cohlhepp, CEO of Bicara Therapeutics. Just as a reminder, this is going to be a 20-minute presentation with roughly five minutes for Q&A at the end, so please keep any questions for the end. Thank you.

Ryan Cohlhepp
CEO, Bicara Therapeutics

Great. First, I'd like to thank Jefferies team for their invitation. Thrilled to be here in London this week. The next six to nine months are a critical junction period for Bicara. We will really be moving to our next era of growth as we move towards our first BLA submission and the potential approval of our lead molecule. I will be making forward-looking statements, so please refer to this slide as well as our SEC disclosures for risk factors. Bicara, we have a single asset. It is an EGFR/TGF-β bifunctional antibody. The drug was designed for the causal biology of tumors, not only that express EGFR, but also those that have high levels of TGF-β, which we know lead to an immunosuppressive tumor microenvironment. The HPV-negative recurrent metastatic tumor is an exemplary example of just that tumor that a drug like Ficera was developed to address.

We've seen the clinical benefit of that, particularly the TGF-β component, as recently at ASCO this last year, we presented data with three years of follow-up, and in that dataset, what the drug was able to demonstrate was the ability to see twice as many patients alive at the three-year mark in comparison to the current standard of care, which is Keytruda monotherapy. We recognize and know that the recurrent metastatic HPV-negative head and neck market is sizable and underserved, with expectations that that market will be in excess of $5 billion by 2030. As a company, we have positioned ourselves based upon having substantially enrolled our pivotal trial to be in a position where we will have top-line data in the middle of next year to prepare our initial BLA submission and the ultimate approval of Ficera in the recurrent metastatic HPV-negative head and neck population.

What we know, again, and why this drug in particular is ideally suited for head and neck cancer, particularly HPV-negative head and neck cancer, it's clear that in that population, there is an overexpression of EGFR and also higher levels of TGF-β. TGF-β matters, particularly because we know that TGF-β leads to acquired resistance mechanisms and for EGFR monoclonal antibodies. Similarly, there is synergy with immunotherapy, particularly PD-1. The clinical benefit of that is what we have seen is deep and durable responses that ultimately have yielded improved overall survival outcomes. Again, we were able to demonstrate that twice as many patients are alive at the three-year mark in comparison to standard of care. What we're seeing across the full population is a meaningful improvement in overall response rates. Again, almost a tripling of overall response rate with 54% of patients in the HPV-negative dataset having responded.

Not only are we seeing a meaningful increase in overall response rates, those response rates are deep and durable. One in four patients, or 25% of patients, have a complete response, and we're seeing that at our 1,500 mg dose, 80% of patients are able to achieve a reduction in their tumor of 80% or greater. That's leading to a median duration of response of 21.7 months. What you see here in the figure to the right is that when you look at those patients where we're able to reduce their overall tumor by 80% or greater, you're able to extend the duration of response in that population to two and a half years. So a meaningful increase in overall duration of response by achieving those deep responses, demonstrating that deep responses matter.

It's also important to contextualize this dataset and the patient population that was included in this dataset. It was a dataset of HPV-negative only patients, which we know prognostically are a much more difficult population to treat than the HPV-positive patients. You also see a good representation based upon the site of disease, with not only patients with distant metastases, who generally do better, but also a good representation of those patients with local regional disease, where again, similar to the HPV-negative population, we know those patients don't do as well. Many of those patients are radiated, which makes delivery to the tumor more difficult. We've got a balanced representation based upon CPS scores, and not only is it a balanced representation, we are seeing very consistent results in both the CPS 1 to 19, as well as the patients with a CPS score of 20 and greater.

What you see here at the bottom is you're also seeing a large number of patients with large bulky disease. These are the patients who historically have been treated with chemotherapy-containing regimens. Again, we saw significant activity in those patients with bulky disease with deep, rapid responses without adding the toxicity of chemotherapy. What that has led to, and again, the representation and the consistency of our dataset gives us confidence as we've gone into our pivotal phase II/III design. This is the study that was initiated in February of last year. We have co-primary endpoints of response rate and overall survival. We initiated the study with a dose optimization phase.

Earlier in the year, we were able to align with regulators that 1,500 mg was the optimal dose, and early this year, we transitioned to the phase III component with 1,500 mg of Ficera plus pembro in a 2:1 randomization against pembro. Last week at earnings, we announced that we had achieved substantial enrollment, which is enabling our ability to do a top-line data cut in the middle of next year. We also, during that earnings call, announced that we will be doing a formal interim analysis for overall survival, and we'll be communicating more details on the timing and that analysis in the future. It's also critical as we think, again, what I was able to show is, again, those patients with deep responses, and the vast majority of our patients, greater than 80% in our phase I experience, were deep responses.

Many of these patients are going to be on therapy for extended durations of time. Being able to provide a dosing schedule that enables those patients to have a dosing schedule that will support and optimize for extended durations of therapy is critical. Here in this study, which we started in the third quarter of this year, is a study designed to show the ability to transition after 12 weeks of weekly therapy to every three-week therapy through progression. The study, again, is designed where at the 12-week mark, we will randomize patients to either remain on weekly therapy or to transition to every three weeks, with the overall endpoint of this trial being able to demonstrate our ability to maintain responses as we decrease the dosing schedule and not see a detriment in progression-free survival.

Again, this is going to be incredibly critical for those patients that we anticipate many of those patients will be on therapy for well over a year for them to optimize for overall patient adherence. With a clinically differentiated profile, we think, again, we are positioned to make a meaningful contribution to the recurrent metastatic HPV-negative population. This is a population that in the U.S., EU5, and Japan represents over 50,000 patients annually, with 18,000 of those patients being in the U.S. While we are significantly expanding the responder population, we are also doing that with deep, durable responses.

As we think about where this drug will benefit patients and from an overall potential, the ability to have increased responder population, longer durations, ultimately delivering meaningful benefits in overall survival, gives us the confidence in our ability to meaningfully contribute to expanding this market to being well over $5 billion by 2030. We're hearing that from the physician community. Over the last year, as we have seen, again, the landscape evolve, one thing that is becoming very clear is that the biology between HPV-positive head and neck cancer and HPV-negative cancer is very different, and we're seeing that in terms of the outcomes across populations. We're also hearing from physicians that complete response and deep response matters, and those deep, durable responses matter because ultimately, physicians believe that will drive differential benefits in overall survival.

We were also consistently hearing that the data that we have demonstrated and presented at multiple medical meetings, that they're seeing the benefit and the translational benefit of TGF-β and how it's contributing to clinical benefits of depth and durability, and ultimately, by making the FORTIFI-FLEX regimen of transitioning to every three weeks will be critical for those patients who will be on therapy for extended durations of time. We also have presented historically our ability to expand beyond the recurrent metastatic head and neck population. We've presented data in the cutaneous squamous cell population. This was a population of patients who were PD-1 refractory, who had not responded to frontline PD-1, and we showed monotherapy activity in that population.

In the anal canal population, we showed activity, including in those patients with liver metastases, and that also, we believe, will translate into the data that ultimately we're building within the colorectal population. We will be presenting our CRC data for the first time at ASCO GI in January of next year. Two cohorts of patients, one a monotherapy cohort, and the second cohort in combination with pembrolizumab. Again, that will be presented during the ASCO GI meeting in the third week of January. While we recognize that there is clear potential for this drug well outside of recurrent metastatic, let me be clear, our number one priority as a company continues to be on the execution of the head and neck program, again, recognizing the ability to see top-line data in the middle of next year, which will enable our first BLA submission as a company.

2026 has really been a key year of operational execution for the company, where we have consistently met or exceeded our commitments to the market in our execution. I'll take you through the timeline. Early this year, again, we aligned with regulators that 1,500 mg was the optimal dose ahead of schedule, allowing us to transition to the phase III component of the trial. At ASCO this year, we demonstrated three years' worth of follow-up, where again, we showed in that data that twice as many patients remained alive at three years versus those that would have been alive with standard of care, Keytruda. We initiated the FORTIFI-FLEX trial in the third quarter of this year and expect that we will have data from that trial ahead of the approval, and our first approval in the recurrent metastatic setting with FORTIFI-HN01.

Last week, we were able to announce that we had met substantial enrollment in our trial, allowing us to be in a position where we expect our top-line data in the middle of next year. Again, that data will support our first submission to the FDA and the BLA submission for the recurrent metastatic population. To summarize, again, I've spoken multiple times around what we believe is a differentiated profile that's going to deliver an outsized benefit, not only in response rate, but more importantly, in overall survival.

This is a large and underserved population where Ficera and the mechanism that we have is uniquely positioned to be able to contribute to the key parameters of response rate and overall survival, with deep, durable responses leading to outsized improvements in overall survival. Finally, we are in a position as a company to move to, again, to our next phase of growth as we prepare for our initial submission and ultimately the approval of Ficera in the recurrent metastatic head and neck population. With that, I'm happy to answer any questions with the remainder of the time.

Speaker 1

Thank you, Ryan. Are there any questions?

Speaker 3

How large is your phase III for head and neck cancer? How many patients? You said substantially. Substantial number of patients have been enrolled, so that includes all your phase II part also in that, right? Just show some clarity on that.

Ryan Cohlhepp
CEO, Bicara Therapeutics

Yeah. The total number of patients that we have in the trial are 650 patients. Again, the phase II component included both the 750 mg patients as well as the 1,500 mg. The 1,500 mg patients in the phase II component will contribute to the efficacy analyses. The 750 mg will only contribute to the safety database. Again, in terms of substantial enrollment, that was the number of patients we need to trigger the interim analysis on response rate. But also, again, this trial is under the framework of the FDA Project FrontRunner, and in that, what the FDA requires is this trial be fully enrolled prior to submission of the BLA.

Speaker 4

Maybe you want to discuss what the implication on the matters of the Genmab update in Bicara, and how you guys looking at it in terms of the impacting your readout.

Ryan Cohlhepp
CEO, Bicara Therapeutics

Yeah, absolutely. Great question. I think probably most people are aware of the data that we saw recently from Genmab in a similar population. Again, the key difference in that study versus our own is it included both HPV-positive and HPV-negative patients. Again, our study is only in the HPV-negative population. What we saw from that dataset in the press release from Genmab was both an overall survival outcome, where they were able to look relatively early in the trial and demonstrate a hazard ratio of 0.5. From an overall response rate perspective, again, what they disclosed in that press release is a statistically significant benefit in response rate across the population.

As we look at that, I think there are two key elements that when we looked at the data, and you look at it both in terms of what we believe is de-risking to the FORTIFI-HN01 trial from an overall data perspective, but also from a competitive differentiation profile. I'll speak first, what we've read through to that from a probability of success perspective. On response rate, what that data would suggest is that the data that was seen in earlier studies with a smaller dataset, probably you're seeing relatively consistent outcomes from an ORR perspective. We see that as very de-risking, that you're not going to see significant deterioration in overall response rate, again, giving us a high degree of confidence in the interim analysis for overall response. From an overall survival perspective, again, that was a 0.5 is meaningful.

We do believe that that's an early look, and a possibility continues to exist that that hazard ratio could deteriorate over time, given when they took the data cut. As we think about the implications for our own study, it has given us even a higher degree of confidence in doing an interim analysis for overall survival in our own trial. Again, last week, we committed to doing that interim analysis for overall survival. Again, we haven't guided to when that will occur, whether it will be at the same time as the response rate analysis or not. But we absolutely have a high degree of confidence in similarly being able to show a meaningful benefit with an early look at overall survival. From a competitive positioning perspective, even as recently as ESMO, we saw updates from their dataset.

We continue to be the only EGFR bifunctional that has been able to demonstrate the complete response rate at 25% or a high proportion of patients with that deep response. Again, the data that I demonstrated in those patients with a greater than 80% response, you're seeing a meaningful improvement in duration of response that we think will ultimately translate into overall survival. So, we saw that data as highly de-risking to our own trial, and when we're taking our cuts for both response rate as well as overall survival, but also maintain our view that we continue to have a differentiated profile from the TGF-β mechanism that's going to drive deep, durable responses, ultimately deliver better overall survival.

Speaker 5

Just to clarify, did you add in the interim overall survival to the trial? Was that there before, or has that been added in post the dates?

Ryan Cohlhepp
CEO, Bicara Therapeutics

Our intent had always been to have an interim analysis for overall survival. That is why we sized the trial 650 from the outset. Again, one of the key distinctions, Merus, after they were acquired by Genmab ultimately increased that trial that we saw recently from 500 to 700. Recently, J&J increased their trial in OrigAMI, which is a triplet regimen versus pembro chemo to 650. We had, from the outset two years ago, had sized at 650, knowing that we were going to incorporate an interim analysis for overall survival. And I think honestly, the reflection of those two trials recently being upsized really is a reflection of the way we had designed our trial from the outset.

Speaker 3

I think if you can comment on recent J&J approval, because at the end of the day, patients are looking at same population of patients.

Ryan Cohlhepp
CEO, Bicara Therapeutics

Yeah. The recent J&J approval was for Rybrevant in the second-line setting. That drug was approved for a population of patients who have progressed on PD-1 plus chemotherapy. Again, going back to the design of our trial, neither one of those arms are chemo-containing arms. Again, I think my read-through to your question, because we have gotten it often, is there any risk around subsequent therapy confounding the outcome of our trial? Given the, again, the two different arms within our trial, both would be off-label for that Rybrevant approval. We expect minimal to no risk from a confounding perspective.

Speaker 1

Thank you. Any more questions?

Ryan Cohlhepp
CEO, Bicara Therapeutics

Great.

Speaker 1

Oh, great.

Ryan Cohlhepp
CEO, Bicara Therapeutics

Well, thank you.